Persistence of Nevirapine in Breast Milk after Discontinuation of Treatment | Zendy

Chantelle BennettoHood | Zendy; Grace M. Aldrovandi | Zendy; Jennifer R. King | Zendy; Kate Woodman | Zendy; Negar Ashouri | Zendy; Edward P. Acosta | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Persistence of Nevirapine in Breast Milk after Discontinuation of Treatment

Author(s) -

Chantelle BennettoHood,

Grace M. Aldrovandi,

Jennifer R. King,

Kate Woodman,

Negar Ashouri,

Edward P. Acosta

Publication year - 2007

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/519427

Subject(s) - nevirapine , discontinuation , medicine , persistence (discontinuity) , breast milk , human immunodeficiency virus (hiv) , virology , antiretroviral therapy , biology , viral load , biochemistry , geotechnical engineering , engineering

The objective of this study was to serially quantitate the concentration of nevirapine in breast milk after discontinuation of treatment. Samples were collected from both breasts of a human immunodeficiency virus-infected patient for 3 weeks. Nevirapine was quantifiable for up to 17 days after discontinuation of therapy; total nevirapine concentrations remained above the 90% inhibitory concentration for 6 days, and no differences were observed between breasts.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research